Celtic Pharmaceutical Holdings L.P.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celtic Pharmaceutical Holdings L.P.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round.
Through a grant from the National Cancer Institute (NCI), Charles River Analytics is building a platform to collect and analyze biometric sensor data and connected devices used by cancer patients across the US. The goal of the project is to support large-scale population health research and to improve cancer outcomes.
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
- Other Names / Subsidiaries
- Auven Therapeutics Management L.L.L.P.
- Celtic Pharma Management
- Xenova Limited
- Celtic Therapeutics Holdings L.P.